Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cure for intermediate or adverse-risk acute myeloid leukemia (AML) (1). It offers patients longer overall survival (OS) (2-4). Unfortunately, human leukocyte antigen (HLA) matched related donor is unavailable in more than 70% patients. Some of these patients, may experience relapse and subsequently achieve CR (non-CR1) with treatment. Some non-CR1 patients eventually receive allo-HSCT. It is unclear whether allo-HSCT will improve the survival of these patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
